NeuroSense Therapeutics Ltd. (NRSNW) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Herzliya, Israel. El CEO actual es Alon Ben-Noon.
NRSNW tiene 17 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $4.88M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
